Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer
Bulat, Iurie, Maglakelidze, Marina, Murias, Carmen, Krastev, Boris, Baird, Richard D, Wardley, Andrew M, Roylance, Rebecca, Crijanovschi, Adrian, Gogiladze, Maia, Pritchett, Yili, McCullough, Amy, Li, Chao, Sorrentino, Jessica A, Malik, Rajesh, Beelen, Andrew P
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article
Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results
Maglakelidze, Marina, Bulat, Iurie, Ryspayeva, Dinara, Krastev, Boris Milev, Gogiladze, Maia, Crijanovschi, Adrian, Aftimos, Philippe Georges, Neven, Patrick, Pegram, Mark D., Menke, Catharina Wilhelmina, Dees, Elizabeth Claire, Schroder, Carolien P., Jager, A., Chap, Linnea I., Hamilton, Erika P., Cristofanilli, Massimo, Ulahannan, Susanna Varkey, Boers, Jorianne, Iqbal, Ramsha, Jain, Sarika
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results
Bulat, Iurie, Maglakelidze, Marina, Murias, Carmen, Kurteva, Galina Petrova, Roylance, Rebecca, Gogiladze, Maia, Crijanovschi, Adrian, McCullough, Amy, Shearin, Elizabeth, Sorrentino, Jessica, Sipes, Christina, Yang, Zhao, Cai, Yaping, Malik, Rajesh K., Beelen, Andrew Paul
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article